Objective-Interleukin (IL)-33 is the most recently described member of the IL-1 family of cytokines and it is a ligand of the ST2 receptor. While the effects of IL-33 on the immune system have been extensively studied, the properties of this cytokine in the cardiovascular system are much less investigated. Methods/Results-We show here that IL-33 promoted the adhesion of human leukocytes to monolayers of human endothelial cells and robustly increased vascular cell adhesion molecule-1, intercellular adhesion molecule-1, endothelial selectin, and monocyte chemoattractant protein-1 protein production and mRNA expression in human coronary artery and human umbilical vein endothelial cells in vitro as well as in human explanted atherosclerotic plaques ex vivo. ST2-fusion protein, but not IL-1 receptor antagonist, abolished these effects. IL-33 induced translocation of nuclear factor-B p50 and p65 subunits to the nucleus in human coronary artery endothelial cells and human umbilical vein endothelial cells and overexpression of dominant negative form of IB kinase 2 or IB␣ in human umbilical vein endothelial cells abolished IL-33-induced adhesion molecules and monocyte chemoattractant protein-1 mRNA expression. We detected IL-33 and ST2 on both protein and mRNA level in human carotid atherosclerotic plaques. Conclusion-We hypothesize that IL-33 may contribute to early events in endothelial activation characteristic for the development of atherosclerotic lesions in the vessel wall, by promoting adhesion molecules and proinflammatory cytokine expression in the endothelium. (Arterioscler Thromb Vasc Biol. 2011;31:
C ardiovascular disease is the leading cause of death in Western societies. 1 Among cardiovascular pathologies atherosclerosis is thought to be the principal contributor to cardiovascular morbidity and mortality. Atherosclerosis is now generally thought to be a chronic inflammatory disorder. [2] [3] [4] Leukocyte trafficking from bloodstream to tissue is important for rapid leukocyte accumulation at sites of inflammatory response or tissue injury. Thus it is evident that leukocyte extravasation is considered a key event in the pathogenesis of atherosclerosis. In fact, endothelial dysfunction, a hallmark in the early development of atherosclerosis is, besides impaired vasomotor function of the vessel wall, characterized by increased adhesiveness of the activated or injured endo-thelium for leukocytes at the site of developing and progressing atherosclerotic lesions. 5 The process of leukocyte extravasation comprises a complex multistep cascade that is orchestrated by a tightly coordinated sequence of adhesive interactions of the leukocytes with vessel wall endothelial cells. Endothelial cells express an array of adhesion molecules that control processes such as leukocyte rolling along and attachment to the endothelium and transmigration of leukocytes into areas of inflammation. 6 These leukocyte-endothelial interactions require the regulated expression of various adhesion molecules by endothelial cells such as intercellular adhesion molecule-1 (ICAM-1), vascular cell AM-1 (VCAM-1) and endothelial selectin (E-selectin). 7 Several studies have demonstrated that these endothelial cell adhesion molecules are upregulated by inflammatory mediators such as interleukin-1 (IL-1) or tumor necrosis factor-␣ (TNF-␣) and that their expression is increased in atherosclerotic lesions. 8 -11 In addition to this process, chemokines such as monocyte chemoattractant protein-1 (MCP-1) attract activated leukocytes to the inflammatory site. 12 Interleukin-33 (IL-33) is the most recently described member of the IL-1-family of cytokines, and it is a ligand of the ST2 receptor. 13 According to the present knowledge, it is suggested that IL-33 is specifically released during necrotic cell death, which is thought to be associated with tissue damage during infection or trauma, but kept intracellular during apoptosis. 14, 15 Because of these properties, IL-33 was proposed to act as "alarmin," as an endogenous "danger" signal to alert the immune system after infection or injury. 14, 16 Consequently, most studies investigating the biological role of IL-33 focus on its immunomodulatory functions. Thus, it was shown that IL-33 is involved in polarization of T-cells toward the T helper type 2 (Th2) cell phenotype as well as in activation of mast cells, basophils, eosinophils, and natural killer cells. 13, [17] [18] [19] IL-33 enhances adhesion, survival, and cytokine production of human mast cells, eosinophils, and basophils. 19 -22 Furthermore, IL-33 was shown to be involved in the modulation of inflammation as it can promote rheumatic and airway inflammatory diseases, anaphylactic shock, and inflammatory and fibrotic disorders of the gastro-intestinal tract. 23, 24 While the effects of IL-33 on the immune system have been extensively studied, 18, 19 the properties of this cytokine in the cardiovascular system are much less investigated. 25, 26 IL-33 and ST2 receptor are expressed in human vein endothelial cells and in coronary artery endothelium, as well as in the thoracic aorta of apolipoprotein E-deficient (ApoE Ϫ/Ϫ ) mice. [27] [28] [29] In such mice, IL-33 was also shown to inhibit the progression of high-fat dietinduced atherosclerosis and the accumulation of foam cells in the lesion. 28, 30 In human endothelial cells, however, IL-33 was shown to induce inflammatory activation as evidenced by increased vascular permeability, the increased production of inflammatory cytokines, and the stimulation of angiogenesis. 27, 31 In this article, we provide evidence for yet another aspect of inflammatory activation of human endothelial cells by IL-33 by showing that this cytokine, which we found to be expressed in human atherosclerotic tissue, stimulates adhesion of leukocytes to the endothelium under both static and flow conditions and upregulates the expression of the adhesion molecules ICAM-1, VCAM-1, and E-selectin and of the chemokine MCP-1 in human endothelial cells in vitro. Furthermore, we demonstrate that the latter effects of IL-33 are also operative in explanted human atherosclerotic plaque tissue ex vivo.
Methods

Cell Culture
Human umbilical vein endothelial cells (HUVEC) were isolated from fresh umbilical cords. Human coronary artery endothelial cells (HCAEC) were isolated from pieces of coronary arteries obtained from patients undergoing heart transplantation. Such endothelial cells were isolated by mild collagenase treatment, characterized and cultivated as described. 32 For some experiments, HCAEC (Lonza, Verviers, Belgium) were used; cells were maintained in EGM-2 MV Bullet kit medium (Lonza) with 5% fetal calf serum (Lonza).
Isolation of Human Polymorph-Nuclear Leukocytes and Monocytes
Human polymorph-nuclear leukocytes (PMNL; 99% neutrophils and less than 1% eosinophils) were isolated from heparinized (100 U/mL) peripheral venous blood of healthy donors as described. 33 For details, please see supplemental material, available online at http://atvb.ahajournals.org. Human monocytes were isolated from peripheral blood mononuclear cells by negative magnetic selection according to manufacturer's instructions (Monocyte Isolation Kit II, MACS, Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of the monocyte preparation was 97%.
Adhesion Assay for PMNL and Monocytes Under Static and Flow Conditions
PMNL adhesion to HCAEC or HUVEC under static conditions was measured as described. 33 PMNL or monocyte adhesion to HCAEC under flow conditions was performed using Venaflux platform (Cellix, Dublin, Ireland). 34 -36 For details, please see online supplemental material.
Tissue Sampling
Atherosclerotic plaques were collected from 35 patients undergoing carotid endarterectomy. All subjects were Caucasian and did not suffer from acute infection or autoimmune or neoplastic disease. For details, please see online supplemental material. The study has been reviewed and approved by the Ethic Committee of the Medical University of Vienna, Austria, and all study subjects gave informed consent.
Treatment of Cells
HCAEC and HUVEC were incubated in minimum essential medium (M199; Sigma) containing 1.25% fetal calf serum (Lonza) without or with recombinant human IL-33 (R&D Systems, Minneapolis, MN) at concentrations between 100 ng/mL and 0.01 ng/mL for time periods between 1 and 48 hours. For soluble receptor inhibition experiments, IL-33 (1 ng/mL) was incubated with recombinant human ST2/IL-1 R4 Fc chimera (sST2-Fc; 5 g/mL, R&D Systems) for 15 minutes at 37°C before addition to the cells for 24 hours, as described previously. 37 In addition, recombinant human immunoglobulin G 1 Fc (IgG 1 -Fc; 5 g/mL, R&D Systems) was used as an isotype control. In order to determine whether the action of IL-33 is dependent on IL-1 effect, HUVEC were cultured for 6 hours in the presence of IL-33 (100 ng/mL) or recombinant human IL-1␤ (200 U/mL; R&D Systems) with or without IL-1 receptor antagonist (IL-1Ra) (10 g/mL; R&D Systems). This concentration of IL-1Ra was shown previously to inhibit IL-1␤-induced ICAM-1 and VCAM-1 expression in HUVEC. 38 In additional experiments, the cells were preincubated for 1 hour with the mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitor U0126 (Promega, Madison, WI), or the phosphatidylinositol 3-kinase (PI3K) inhibitor LY-294002 (Calbiochem/Merck, Darmstadt, Germany) at the indicated concentrations that were similar to concentrations used by us and others in in vitro studies with endothelial cells. 39 -42 Thereafter, the cells were treated with IL-33 at a concentration of 100 ng/mL for 24 hours (for ICAM-1, VCAM-1, MCP-1 measurement) or 4 hours (for E-selectin determination). TNF-␣ (Roche Diagnostics, Indianapolis, IN) at 10 pM was used as a positive control in our experiments. The culture supernatants were collected followed by removal of cell debris by centrifugation and stored at Ϫ80°C until used. The total cell number was counted with a hemocytometer after trypsinization.
Flow Cytometry
ICAM-1, VCAM-1, and E-selectin expressions at the cell surface were measured by means of flow cytometry (FACS Canto II, Becton Dickinson, Franklin Lakes, NJ). For details, please see online supplemental material.
Antigen Determination
MCP-1, IL-6, and IL-8 antigen in cell culture supernatants or in supernatants from stimulated explanted atherosclerotic plaque tissue was measured by specific ELISAs using monoclonal antibodies (all from Bender MedSystems, Vienna, Austria).
Total RNA Purification and cDNA Preparation
mRNA was isolated using High Pure RNA Tissue Kit (Roche). Reverse transcription was performed using Transcriptor First Strand cDNA Synthesis Kit (Roche). For details, please see online supplemental material.
RealTime Polymerase Chain Reaction
RealTime-PCR was performed using LightCycler TaqMan Master (Roche) according to the manufacturer's instructions. For details, please see online supplemental material.
Nuclear Extraction and Analysis of NF-B/DNA Binding
Preparation of nuclear extracts was performed using a Nuclear Extract Kit (Active Motif, Rixensart, Belgium) according to the manufacturer's instructions. For details, please see online supplemental material.
NF-B Translocation Staining
HCAEC were treated with fresh M199 containing 1.25% fetal calf serum without or with 1, 10, or 100 ng/mL IL-33 for 1 hour and staining for NF-B p50 and p65 subunits was performed. For details, please see online supplemental material.
Immunofluorescence Analysis of IL-33 and ST2 in Human Atherosclerotic Tissue
Human carotid endatherectomy tissues were fixed in 4% formaldehyde and embedded in paraffin. Sections (5 m) were deparaffinized according to standard procedure and then boiled for antigen retrieval in citrate buffer (DAKO North America, Inc, CA). The following primary antibodies were used: mouse monoclonal antibody anti-IL33 (clone Nessy-1, 1:1000 dilution; Alexis Biochemicals, Enzo Life Sciences AG, Lausen, Switzerland), rabbit polyclonal antibody anti-ST2 (IL1RL1) (1:100 dilution; Sigma), and rabbit polyclonal antibody anti-von Willebrand factor (1:500 dilution; Dako). For details, please see online supplemental material.
Adenoviral Infection
HUVEC were infected with adenoviral vectors for overexpression of IB␣ (AdV-IB␣) or for overexpression of a mutant dominant negative IB kinase 2 (AdV-dnIKK2), respectively, as described previously. 43, 44 For details, please see online supplemental material.
Statistical Analysis
ANOVA followed by Bonferroni-Holm multiple comparisons correction was carried out for experiments having more than 2 experimental groups. Dunnett's post-hoc test was used to compare treated groups with the reference untreated group. Normally distributed data were analyzed with t tests in case of 2 groups. Mean concentrations of the respective protein for each plaque before and after stimulation with IL-33 were compared using Wilcoxon signed-rank test for nonparametric distribution. For mRNA correlation, a Spearman correlation for nonparametric variables was calculated using SPSS 16.0 (SPSS, Chicago, IL). Values are expressed as meanϮSD. Values of PՅ0.05 were considered significant.
Results
IL-33 Promotes Adhesion of Human Leukocytes to the Monolayer of Endothelial Cells
When HCAEC were pretreated with 100 ng/mL IL-33 for 4 hours, an increase in the number of PMNL adhering to the endothelial cell monolayer was seen already 5, 15, and, more prominently, 30 minutes after the addition of PMNL as compared to untreated control ( Figure 1A Under flow conditions (0.5 dyne/cm 2 for 2 minutes and 20 seconds at 37°C), IL-33 at concentrations of 10 ng/mL and 100 ng/mL induced statistically significant (PՅ0.05) adhesion of both PMNL and monocytes to monolayers of HCAEC ( Figure  1C and 1D). TNF-␣ at 10 pM, used as a positive control, also significantly increased adhesion of both PMNL (control 8Ϯ4, TNF-␣ 107Ϯ26, PՅ0.05) and monocytes (control 4Ϯ2, TNF-␣ 10Ϯ1, PՅ0.05) to HCAEC under flow condition. To address which adhesion molecules might mediate the PMNL adhesion, we also performed additional experiments with blocking antibodies against E-selectin, ICAM-1, and VCAM-1 alone, or with all three blocking antibodies together. E-selectin and VCAM-1 antibodies significantly (PՅ0.05) reduced PMNL adhesion to HCAEC monolayers which had been activated by 10 ng/mL of IL-33 ( Figure 1E and 1F). ICAM-1 antibody also reduced IL-33-mediated PMNL adhesion, however, to a lesser extent than E-selectin or VCAM-1 antibodies ( Figure 1E and 1F ). If all 3 antibodies were applied simultaneously, IL-33-induced PMNL adhesion was reduced to the level of untreated endothelial cells ( Figure  1E and 1F). Please see, also, respective movies in the supplemental data.
IL-33 Stimulates VCAM-1, ICAM-1, E-Selectin, and MCP-1 Expression in Human Endothelial Cells via ST2 Receptor and in IL-1-, MEK-, and PI3K-Independent Manner
When HUVEC were treated with IL-33 at concentrations from 0.01 to 100 ng/mL for 4, 16, 24, and 48 hours, a concentrationdependent upregulation of ICAM-1, VCAM-1, and MCP-1 protein production was observed at all time points (Figure 2A , B, D). E-selectin expression was also significantly increased in these cells, however, only after 4 hours of incubation ( Figure  2C ). TNF-␣ at 10 pM induced upregulation of these adhesion molecules and MCP-1 with similar kinetics in HUVEC (ICAM- hours with IL-33 (100 ng/mL). HBSS (1.0 mL) containing 1ϫ10 6 /mL PMNL was then added to the endothelial cell monolayer for 5, 15, and 30 minutes. Respective photomicrographs are shown. B, Adhesion of polymorph-nuclear leukocytes (PMNL) to monolayers of HCAEC was determined as described in "Methods." Experiments were performed twice. Values represent numbers of PMNL per 5ϫ10 5 square (sq) microns and are given as meanϮSD of 10 pictures, respectively. Original magnification ϫ100. *PՅ0.05 compared to control. C, HCAEC were grown on VenaEC biochips and preincubated for 4 hours with IL-33 (10 or 100 ng/mL). Endothelial monolayers were then superfused with suspensions of 3x10 6 /mL PMNL or monocytes at 0.5 dyne/cm 2 for 2 minutes and 20 seconds at 37°C using Venaflux Nanopump. Part of the respective photomicrographs is shown. D, Adhesion of PMNL or monocytes to monolayers of HCAEC was determined as described in "Methods." Experiments were performed 4 times, and 10 images were made at each experiment. Values represent numbers of PMNL or monocytes per 5ϫ10 5 sq microns and are given as meanϮSD of 40 pictures, respectively. Original magnification ϫ100. *PՅ0.05 compared to control for PMNL. §PՅ0.05 compared to control for monocytes. E, Endothelial cell layers were preincubated for 4 hours with or without 10 ng/mL of IL-33. Afterward, the cells were incubated with blocking antibodies for E-selectin, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) (10 g/mL each), or all three antibodies together (5 g/mL each), or with an isotype matched control antibody at the same concentrations for 15 minutes at 37°C followed by superfusion with suspensions of 3ϫ10 6 /mL PMNL at 0.5 dyne/cm 2 for 2 minutes and 20 seconds at 37°C. Part of the respective photomicrographs is shown. F, Adhesion of PMNL to monolayers of HCAEC was determined as described in "Methods." Experiments were performed 4 times, and 10 photos were made at each experiment. Values represent numbers of PMNL per 5ϫ10 5 8594). In agreement with published data, IL-6 and IL-8 protein production was also increased under IL-33 treatment in both endothelial cell types (data not shown). 31 Also in HCAEC, IL-33 treatment dose-dependently increased ICAM-1 (Figure 2E ), VCAM-1 ( Figure 2F ), E-selectin ( Figure 2G ), and MCP-1 protein ( Figure 2H ) after 4 hours of incubation.
As IL-33 was shown to exert its effects by binding to cell surface T1/ST2, 13 we examined whether incubation with the soluble extracellular domain of ST2 coupled to the Fc fragment of human IgG 1 (sST2-Fc) could interfere with the stimulatory effect of IL-33. Indeed, sST2-Fc, but not IgG 1 -Fc used as an isotype control, significantly inhibited the production of ICAM-1, VCAM-1, E-selectin, and MCP-1 protein induced by IL-33 in human endothelial cells (Supplemental Figure I) . sST2-Fc does not affect basal production of any of these proteins (Supplemental Figure I) .
IL-33 at a concentration of 100 ng/mL also robustly upregulated mRNA specific for ICAM-1, VCAM-1, E-selectin and MCP-1 in HUVEC between 1 hour and 9 hours of incubation with maximal up-regulation between 3 and 6 hours (please see Supplemental Figure II ). Similarly, levels of mRNA specific for ICAM-1, VCAM-1, E-selectin, and MCP-1 were increased also in HCAEC after 9 hours of incubation with 100 ng/mL IL-33 12.0Ϯ5.1-fold, 17.9Ϯ4.1-fold, 246.2Ϯ51.9-fold, and 9.4Ϯ3.7-fold, respectively.
We tested also for the effect of IL-33 treatment on IL-1 expression and found that IL-33 also significantly upregulated IL-1 mRNA expression in both HUVEC and HCAEC (Supplemental Table I ). Maximal upregulation of IL-1 mRNA was achieved at 6 hours in HUVEC and at 3 hours in HCAEC ( Supplemental Table I ). Since ICAM-1, VCAM-1, E-selectin, and MCP-1 production may also depend on the autocrine action of IL-1, we determined the role of endogenous IL-1 in the production of these biomolecules by IL-33. We found no inhibitory effect of IL-1Ra (10 g/mL) on IL-33-induced ICAM-1, VCAM-1, E-selectin, and MCP-1 mRNA expression in HUVEC. In contrast, when used at the same concentration IL-1Ra completely inhibited IL-1␤induced mRNA expression of these proteins ( Supplemental  Table II ).
As IL-33 was previously shown to activate Erk1/2 31 and PI3K/Akt 27 pathways in endothelial cells, we tested in additional experiments whether the MEK inhibitor U0126 or PI3K inhibitor LY-294002 could modify IL-33-induced ICAM-1, VCAM-1, E-selectin, or MCP-1 protein production. As shown in Supplemental Table III , neither U0126 at concentration 1 mol/L nor LY-294002 at concentration 5 mol/L abrogated IL-33-induced ICAM-1, VCAM-1, E-selectin, or MCP-1 proteins.
As IL-33 is known to exert a Th2 polarizing effect, 13 we also investigated the production of the Th2 cytokines IL-4 and IL-5 and the T regulatory cytokine IL-10 45 in human endothelial cells after treatment with IL-33. As shown in Supplemental Figure III, IL-33 at 100 ng/mL did not modulate the production of IL-4, IL-5, or IL-10 in HCAEC at any time point tested (4, 16, and 24 hours).
IL-33 Induces NF-B Nuclear Translocation and IL-33 Effects on Endothelial Cells are NF-B-Dependent
As can be seen in Figure 3 (Table) .
IL-33 and ST2 Protein and mRNA Are Expressed in Human Atherosclerotic Plaque and Recombinant IL-33 Induces a Proadhesive and Proinflammatory State in Explanted Atherosclerotic Plaque Tissue
As shown on Figure 4 using fluorescence immunohistochemistry, we detect both IL-33 and ST2 protein in human carotid endatherectomy specimens. IL-33 protein is expressed by endothelial cells as shown by colocalization with von Willebrand factor ( Figure 4A ). Nuclear IL-33 expression and membrane-bound ST2 expression was found on the same cells ( Figure 4B and 4C ). Using RealTime-PCR, we detected also mRNA specific for IL-33 and ST2 in human carotid plaques samples. Moreover, we found a positive correlation between IL-33 mRNA and ST2 mRNA expression (rϭ0.566; Pϭ0.044; Figure 4D ) in atherosclerotic tissue. In order to determine whether the effect of IL-33 on the expression of adhesion molecules and MCP-1 seen in vitro is reproducible in an ex vivo situation, we treated explanted human carotid atherosclerotic plaques with IL-33 for 24 hours (nϭ12) to determine MCP-1, IL-6, and IL-8 protein, or for 6 hours (nϭ7) to assess ICAM-1, VCAM-1, E-selectin, MCP-1, IL-6, and IL-8 mRNA. As shown in Figure 5 , IL-33 significantly increased ICAM-1 mRNA (Pϭ0.018), VCAM-1 mRNA (Pϭ0.028), E-selectin mRNA (Pϭ0.018), MCP-1 mRNA (Pϭ0.018), and IL-6 mRNA (Pϭ0.018) expression as well as MCP-1 protein (Pϭ0.031), IL-6 protein (Pϭ0.00006) and IL-8 protein (Pϭ0.003). IL-8 mRNA level also increased. However, the difference did not reach statistical significance (Pϭ0.063, data not shown).
Discussion
Leukocyte interaction with vascular endothelial cells is a pivotal event in the inflammatory response characteristic for many pathologies including atherosclerosis. 6 Circulating leukocytes adhere poorly to healthy endothelium under physiological conditions. When the endothelium becomes activated, however, it expresses adhesion molecules that bind cognate ligands on leukocytes. This switch from a resting, antiadhesive to an inflammatory activated, adhesive endothelium is a key event in the development of endothelial dysfunction, which is considered a hallmark in the early pathogenesis of atherosclerosis. Selectins are involved in the rolling and tethering of leukocytes on the vascular wall. ICAM-1 and VCAM-1 induce firm adhesion of inflammatory cells at the vascular surface. 5, 7 Chemokines such as MCP-1 provide a chemotactic stimulus to the adherent leukocytes, directing their diapedesis and migration into the vessel wall. 12 Classical inflammatory mediators such as IL-1 and TNF-␣ were shown to induce VCAM-1, ICAM-1, and E-selectin in human endothelial cells. 8, 9 Here, we show for the first time that the novel IL-1 cytokine family member, IL-33, induces rapid adhesion of leukocytes to monolayers of human endothelial cells isolated from coronary artery and umbilical vein. On further analysis, we could show upregulation of the production of the adhesion molecules VCAM-1, ICAM-1, E-selectin, and the chemokine MCP-1 in these endothelial cells by IL-33. The upregulation of these adhesion molecules was concentration-dependent with a significant increase seen at concentrations between 1 ng/mL and 100 ng/mL of IL-33. In agreement with a recently published study, we found that IL-33 also upregulated the inflammatory cytokines IL-6 and IL-8 in human endothelial cells. 31 In parallel with increased VCAM-1, ICAM-1, E-selectin, and MCP-1 protein production, IL-33 caused a marked upregulation of specific mRNA for VCAM-1, ICAM-1, E-selectin, and MCP-1 in human coronary artery and umbilical vein endothelial cells. The effect was specific for IL-33 because sST2-Fc but not IgG 1 -Fc abrogated these IL-33-induced effects in endothelial cells. We also showed that IL-33 HUVEC were left uninfected or were infected with a recombinant adenovirus expressing dnIKK2 (AdV-dnIKK2), IB␣ (AdV-IB␣) or a control adenovirus (AdV-GFP) for 4 -6 h. 48-h post infection cells were stimulated with Interleukin-33 (100 ng/mL) for 6 h whereas control cells were left untreated. mRNA was prepared and RealTime-PCR with primers specific for intercellular adhesion molecule-1 (ICAM-1), vascular cell AM-1 (VCAM-1), endothelial selectin (E-selectin), monocyte chemoattractant protein-1 (MCP-1), and GAPDH was performed as described in "Methods." Each experiment was performed in triplicates. Adhesion molecules and MCP-1 mRNA levels were normalized according to the respective GAPDH mRNA level. Values are given as x-fold of control, which was set as 1 and represent mean valuesϮSD of 2 different experiments. The overall ANOVA for each tested molecule remained significant after correction for 4 comparisons.
exerted direct proinflammatory properties on human endothelial cells without a requirement for intermediate autocrine or juxtacrine action of IL-1␤, as the natural antagonist IL-1Ra, which inhibits IL-1␤ action by preventing its binding to specific receptors, did not inhibit IL-33-induced upregulation of ICAM-1, VCAM-1, E-selectin, or MCP-1 specific mRNA in these cells. We also show that IL-33 induces nuclear translocation of NF-B p50 and p65 subunits in both types of endothelial cells suggesting that the effects of IL-33 are mediated via the NF-B pathway. This notion is further supported by our finding that the stimulatory effect of IL-33 on adhesion molecule and MCP-1 expression is abolished by adenoviral overexpression of IB and dnIKK in these cells. In agreement with our observations, IL-33 has been shown to activate NF-B in various other cell types such as mast cells, 13, 20, 46 eosinophils, 47 basophils, 18 CD4 ϩ T-cells 48 and rat neonatal cardiac myocytes and fibroblasts. 25 Although IL-33 was previously shown to activate Erk1/2 and Akt pathways, 27, 31 MEK inhibitor U0126 or PI3K inhibitor LY-294002 did not abrogate induction by IL-33 of any of the proteins tested in our study.
Moreover, we found that IL-33 and ST2 are expressed in human atherosclerotic carotid tissue on both protein and mRNA level. Our study is the first that demonstrated expression of both IL-33 and ST2 in human atherosclerotic tissue. IL-33 protein is localized to endothelial cells in human atherosclerotic tissue. It should be emphasized that a previous study demonstrated increased IL-33 expression in the atherosclerotic aorta of ApoE Ϫ/Ϫ mice fed a high-fat diet as compared to ApoE Ϫ/Ϫ mice fed a normal diet and to wild-type mice. 28 Here, we describe that in human atherosclerotic plaques nuclear IL-33 and membrane-bound ST2 protein are expressed by the same cells, namely by endothelial cells, and that IL-33 mRNA significantly correlates with ST2 mRNA expression in carotid atherosclerotic tissue, suggesting that both proteins are highly coregulated in this tissue. Furthermore, ex vivo treatment of atherosclerotic tissue samples with IL-33 increased the expression of ICAM-1, VCAM-1, E-selectin, and MCP-1 in these tissue specimens.
Since the discovery of IL-33 in 2005, numerous immunomodulator effects of this cytokine were described in different cells. IL-33 enhances adhesion and survival of mast cells, eosinophils and basophils, as well as release of different cytokines from these cells, and is a chemoattractant for Th2 cells in vitro. 19 -22,49 Furthermore, it was shown recently that IL-33 upregulated cell surface expression of the adhesion molecule ICAM-1 on eosinophils, but it suppressed that of ICAM-3 and L-selectin. 47 In an in vivo experimental sepsis model, IL-33 treatment increased neutrophil influx into the peritoneal cavity and induced more efficient bacterial clearance, which was associated with reduced mortality. 50 In a murine model of collageninduced arthritis, IL-33 treatment markedly exacerbated mononuclear and polymorphonuclear cell infiltration into the joint which was associated with disease progression. 51 Taken together, IL-33 appears to be an important immune regulator that plays a role in inflammation, especially in the rapid recruitment of certain effector cells into sites of ongoing inflammation.
Compared to these effects of IL-33 on the immune system, data on its contribution to cardiovascular pathophysiology is scarce. In human endothelial cells, IL-33 induced inflammatory activation as evidenced by increased vascular permeability, increased production of inflammatory cytokines, and the stimulation of angiogenesis. 27, 31 A possible role for IL-33 in the development and progression of atherosclerosis is suggested but not well characterized yet. IL-33 was shown to be expressed in cells that are known to be present in atherosclerotic lesions and to activate such cells. 2, 3 For example, IL-33 was found in coronary artery endothelium, 29 and was shown to induce the production of proinflammatory cytokines from human mast cells and T-cells and to enhance lipopolysaccharide (LPS)-induced TNF-␣, IL-6, and IL-1␤ production from macrophages. 24, 52, 53 It should be noted that recently generated IL-33-deficient mice showed a substantially diminished LPS-induced systemic inflammatory response. 54 Furthermore, IL-33 mRNA expression was found in human endothelial cells, coronary artery smooth muscle cells, and peripheral blood monocytes and leukocytes. 13, 28, 29, 55 In contrast to our data presented here, which suggest a detrimental contribution of IL-33 to the early development of atherosclerosis, in ApoE Ϫ/Ϫ mice fed on a high-fat diet treatment with IL-33 had reduced atherosclerotic lesions in the thoracic aorta via increased IL-5 and oxidized low density lipoprotein auto-antibody production as well as by decreased macrophage foam cell formation. 28, 30 It should be noted, however, that in these latter studies, which showed antiatherosclerotic effects of long-term administration (6 weeks) of IL-33, 1 g/injection of the cytokine was administered into ApoE Ϫ/Ϫ mice that already had developed atherosclerosis. 28, 30 IL-33 administration increased Th2 cytokines, IL-4, IL-5, and IL-13, and reduced the Th1 cytokine IFN-␥ by lymph node cells in vitro and in serum ex vivo. 28 The level of the Th17 cytokine IL-17 was not different in lymph node cells between IL-33-and PBS-treated animals, and IL-17 and IL-10 serum levels were not detectable. Local cytokine expression in the vasculature ex vivo was not investigated in this study. There is strong evidence supporting a proatherogenic role of Th1 cells, whereas a possible contribution of the Th2 subset in atherosclerotic lesion formation is controversially discussed. 45, 56 The role of the Th2 pathway in the development of atherosclerosis seems to be depending on the stage and site of the lesion, and on the experimental model. 57 Both anti-and proatherogenic effects of IL-4, another prototypical Th2 cytokine, and IL-17, a cytokine produced by Th17 cells, were shown in different studies using different experimental approaches. 57 It should be noted that Th2 cell induction is promoted in severe hyperlipidemia, 58 and under these conditions Th2 cytokines could be a target for IL-33 as shown in this experimental mouse model of atherosclerosis. 28, 30 These contradictory findings could be also explained on the basis of different roles for IL-33 and ST2 in distinct ST2-expressing cells. In support of that concept, IL-33 is able to enhance the production of the Th1 cytokine IFN-␥ by natural killer cells and invariant cells, 22, 59 which are found in atherosclerotic lesions and are thought to be involved in the pathogenesis of atherosclerosis. 60 It is of interest that in our study recombinant human IL-33 at 100 ng/mL did not affect the production of the Th2 cytokines IL-4 and IL-5 and the T regulatory cytokine IL-10 in human coronary artery endothelial cells.
Upregulation of adhesion molecules and chemokines in endothelial cells as shown here by us is, besides an impaired vasomotor function, a key event in endothelial dysfunction that is considered to be an early hallmark in the pathogenesis of atherosclerosis. 2, 3 It should also be emphasized that in one of the articles mentioned above IL-33 injection into the mice enhanced their IL-6 serum levels. 28 IL-6 has been shown to contribute to development of atherosclerotic lesions, and its serum levels correlate with poor prognosis in humans with cardiovascular disease and are an independent predictor of sudden death in asymptomatic men. [61] [62] [63] Furthermore, it should be noted that IL-33 was shown to be associated with other human inflammatory pathologies such as rheumatoid arthritis, systemic sclerosis, inflammatory bowel disease, chronic pancreatitis, asthma, psoriasis, and anaphylactic shock. 23, 24 However, the mechanisms of the deleterious effects of IL-33 in these disorders are not completely understood yet.
In conclusion, we provide evidence for the first time that the latest member of the IL-1 cytokine family, the "alarmin" IL-33, 14, 16 is present in human atherosclerotic lesion and stimulates the expression of the adhesion molecules ICAM-1, VCAM-1, E-selectin, and the chemokine MCP-1 in atherosclerotic tissue ex vivo and in human coronary artery and umbilical vein endothelial cells in an IL-1, MEK-and PI3K-independent but ST2-and NF-Bdependent manner in vitro. Given the fact that the expression of ICAM-1, VCAM-1, E-selectin, and MCP-1 in atherosclerotic lesions has been reported to increase during atherogenesis and that this expression seems to be directly associated with plaque progression, 2,3,10,11 we hypothesize that IL-33, by promoting adhesion molecules and proinflammatory cytokine expression in the endothelium as well as adhesion of blood cells to the endothelium, may contribute to early events in endothelial dysfunction characteristic for the development of atherosclerotic lesions in the vessel wall.
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